CATX biotech catalysts & pipeline

PERSPECTIVE THERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

[ 212 Pb]VMT-α-NET — Interim data

late 2026

Updated [ 212 Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were consistent with previously disclosed findings at AACR as of March 4, 2026 with continued deepening of responses; additional updates expected in late 2026

Source filing

[212Pb]PSV359 — Interim data

late 2026

[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026

Source filing

[212Pb]PSV359 — Initial data

in 2027

The next clinical update is planned in 2027.

Source filing

lapemelanotide zapixetar (VMT01) — Conference presentation

Nov 4–Nov 8

Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026

Source filing

bamzireotide navoxetan (VMT-α-NET) — Conference presentation

Nov 5

The Company will present additional data in the coming weeks: at the NANETS 2026 Multidisciplinary NET Medical Symposium, November 5, 2026, and the EORTC-NCI-AACR (ENA) Symposium, November 20, 2026.

Source filing

bamzireotide navoxetan (VMT-α-NET) — Conference presentation

Nov 20

The Company will present additional data in the coming weeks: at the NANETS 2026 Multidisciplinary NET Medical Symposium, November 5, 2026, and the EORTC-NCI-AACR (ENA) Symposium, November 20, 2026.

Source filing

Explore the free biotech catalyst calendar